Traws Pharma, Inc. — Director's Dealing 2025

Feb 20, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Traws Pharma, Inc. (TRAW)
CIK: 0001130598
Period of Report: 2025-02-18

Reporting Person: CAUTREELS WERNER (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-02-18	Common Stock	M	96348	$0.01	Acquired	104348	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-02-18	Pre-Funded Warrant (right to buy)	$0.01	M	96348	Disposed		Common Stock (96348)	Direct

Footnotes

F1: The Common Stock was acquired by way of an exercise of Pre-Funded Warrants at an exercise price of $0.01 per Pre-Funded Warrant. The Pre-Funded warrants were acquired as part of Class B Units, with each Class B unit consisting of one Pre-Funded Warrant and one Series A Warrant, at a purchase price of $5.093 per Class B Unit.

F2: The Pre-Funded Warrants became exercisable upon stockholder approval on February 17, 2025.

F3: The Pre-Funded Warrants do not expire.